glp-1 agonists anxiety side effects and Anxiety: What the Evidence Shows – Bolt Pharmacy The GLP-1 Agonists and Obesity:

The GLP-1 receptor agonists used clinically are based on exendin-4 and native GLP-1 and are available as formulations for daily or weekly s.c

Glucagon-like peptide-1 receptor agonist (GLP-1RAs) and more recently Twin-Cretins (GLP+GIP) are frequently used for patients with diabetes and associated obesity

Anyway, we are currently facing a novel and very appealing therapeutic option.

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

Future research should focus on elucidating the complex mechanisms underlying their psychological effects and integrating mental health considerations into therapeutic strategies